Completed PHASE3 INTERVENTIONAL 3-arm NCT04591210

The COVID-RASi Trial (COVID-19)

Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial

Sponsor: Ottawa Heart Institute Research Corporation

Conditions COVID-19 Cardiovascular Diseases

Interventions Angiotensin II Receptor Blockers Angiotensin converting enzyme inhibitor

Updated 12 times since 2020 Last updated: Jan 26, 2026 Started: Jan 27, 2021 Primary completion: Dec 30, 2024 Completion: Dec 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on COVID-19 and Cardiovascular Diseases, this trial is completed. The trial is conducted by Ottawa Heart Institute Research Corporation and has accumulated 12 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

12 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 7 earlier versions

Jun 2023 — Mar 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE3
Mar 2021 — Sep 2021 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Mar 2021 [monthly]

Not Yet Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ottawa Heart Institute Research Corporation

Data source: Ottawa Heart Institute Research Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Azcapotzalco, Mexico , Belo Horizonte, Brazil , Bragança Paulista, Brazil , Campinas, Brazil , Campo Grande, Brazil , Canoas, Brazil , Consolação, Brazil , Curitiba, Brazil , Ecatepec de Morelos, Mexico , Edmonton, Canada and 15 more locations